17,261 trials
Coronary Artery Disease · Myocardial Ischemia · Coronary Disease
Primary: Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB) — 18.8; 22.2 ng/mL
Malignant Mesothelioma
Primary: Progression-Free Survival — 3.0 months
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Progression-free Survival — 3.5; 5.4 Months
Acute Coronary Syndrome
Primary: Change in Percent Inhibition of Platelet Aggregation (%IPA) — 99.59; 99.88 percentage of IPA
Hepatitis C Infection With HIV Co-Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12) — 76.9 percentage of participants
Lymphoma
Primary: Clinical Response Rate — 2; 0; 1; 1 participants
Breast Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity in Phase I — 2; 0 participants with DLTs
Breast Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity in Phase I — 0; 3 participants with DLTs
Giant Cell Glioblastoma · Glioblastoma · Gliosarcoma
Primary: Number of Patients Experiencing of Dose-limiting Toxicity (Cohort 1) — 0 participants
Leukemia · Lymphoma
Primary: Overall Objective Response — 10; 5; 26; 4 Participants
HIV Infections
Primary: Self-reported Adherence to Each Regimen — 94; 93.8; 93.9 percentage of expected doses
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Allergic Conjunctivitis
Primary: Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]) — 2.65; 2.68; 3.07; 2.88 units on a scale — p=0.3235
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
Stroke
Primary: Change in Action Research Arm Test (ARAT) Score Per Week — 0.4; -0.05; 0.31; 0.66 change in units on a scale/week — p=.01